Advertisement
Advertisement
2026 Digital Exclusive No. 3
The New Rules of TAVR: What the CMS NCD Means for Aortic Stenosis Care
How the revised TAVR coverage requirements could affect patient access, procedural workflows, heart team decision-making, and quality oversight.
What are the likely effects of the new Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD)1 on patient access to transcatheter aortic valve replacement (TAVR) care?
Theoretically, the NCD is supposed to allow for better access to care. Whether it does remains to be seen. One of the challenges that some programs have dealt with is the requirement to have both a surgeon and interventionalist see the patient together (or do the procedure together), which limited the timeliness of treatment. Patient access/treatment would depend on both the interventionalist's and surgeon's schedule. With the NCD, programs can now choose to have one operator present at appointments. So, theoretically, the NCD should help free up providers.
What do you see as the potential advantages of the changes to the procedure evaluation requirements?
The evaluation requirement mandates that a TAVR operator must see the patient face-to-face (it can't be a virtual visit), and everyone on the heart team has to be made aware of that the evaluation is taking place. However, with this change, the patient doesn't have to be seen by two different operators (the interventionalist and surgeon) to complete the evaluation step. The evaluation has to be seen by all of the heart team.
However, many established TAVR programs, particularly larger ones, will continue to require two operators to be present for evaluations, consistent with the requirement under the previous NCD. The new NCD does not mean that every program is going to change—it just frees up access. The NCD specifically states coverage is not affected if programs would like to continue with the two-operator evaluation requirement.
I also think it is important to emphasize that this change does not reduce payment; it simply removes the requirement for two operators. The clinic evaluation must still be reviewed by the heart team, which must continue to meet, and the information must be available to all team members. The NCD is clear about preserving the heart team’s role while making it easier for patients to be evaluated by a TAVR operator.
How should TAVR groups ensure that no quality is lost when stepping down to a single operator, and for which cases do you think it's best to have two operators on hand?
Our program will continue to involve both a surgeon and an interventionalist because this approach works well for us. Programs that adopt a different model will be responsible for maintaining the same quality of care, including monitoring their quality metrics to ensure that patients receive appropriate care.
Will most programs retain two operators, or will the NCD lead to broader changes?
It depends on the program. Larger programs may maintain their current approach. For smaller programs that struggle to coordinate surgeon and interventionalist availability, the change could expand scheduling flexibility by allowing procedures with one operator.
For programs like ours, continued payment for two operators is reassuring. We see substantial value in this approach and have built our program around it.
What are the possible day-to-day implications of moving to a single operator model for the interventional cardiology division and for overall hospital efficiency?
Time will tell exactly what these changes will mean for individual programs. One potential challenge is the future of the Transcatheter Valve Therapy (TVT) Registry and whether we will continue to have a reliable way to collect data and evaluate how programs are performing. Maintaining that ability to track outcomes will be an important issue moving forward.
What does the CMS's ending of the coverage with evidence development (CED) for TAVR in symptomatic aortic stenosis (AS) signal in terms of recognition for TAVR? What are the potential ramifications of ending the CED?
I understand why they ended the CED. The purpose of the CED was to establish the evidence base, and we now have sufficient evidence demonstrating that TAVR is beneficial in patients with symptomatic AS.
One of the ramifications, however, involves data collection. Until now, we were required to enter every TAVR procedure into the TVT Registry. If we had a question about outcomes, we could turn to the registry because essentially every patient undergoing TAVR was represented. Without a registry requirement, it becomes more difficult to collect that information and understand outcomes because there is no longer a single, comprehensive source of data.
It remains to be seen whether TAVR will eventually follow a model similar to the Society of Thoracic Surgeons (STS) database. Although participation in the STS database is not mandatory, it is connected to public reporting, outcomes, and the STS star-rating system. It will be interesting to see whether TAVR ultimately adopts a similar approach, with a voluntary registry in which programs can submit their data and potentially participate in a comparable quality-rating system. There are ongoing discussions about what that might look like, but I don’t think anyone knows yet exactly how it will evolve.
Treatment of asymptomatic severe AS is now covered under the CED. What questions most need answering in this continued real-world study of TAVR in this setting?
We still want to understand whether earlier intervention is truly beneficial and ensure that we are not trading durability for earlier valve replacement. The EARLY TAVR trial suggested that earlier intervention reduced adverse outcomes, including hospitalizations and stroke, without an apparent penalty in terms of valve durability.2 Although it was a randomized controlled trial, we still want to see whether those findings are borne out in real-world data.
The NCD also removes the minimum hospital TAVR thresholds while maintaining them for operators. How might this affect access to care and who can deliver it?
The goal is to improve access by removing hospital requirements and setting minimum physician requirements. The effect on quality remains to be seen, making a registry essential for tracking outcomes.
The NCD essentially assumes that a hospital with a surgical program can support TAVR. Because surgical programs have no comparable hospital-level requirements, it applies the same principle to TAVR.
What final thoughts do you want to convey to our readers about the NCD?
I think the NCD gives programs the flexibility to provide this therapy without worrying that patients may face delays because two physicians cannot be present at the same time. It allows programs to focus on delivering the care their patients need while placing the responsibility on each program to monitor and maintain quality—which is something they should be doing anyway.
In the end, I think the NCD was quite fair. It does not restrict programs that have been successful using a two-operator model. Those programs can continue with the approach that has worked well for them.
I agree with the NCD in allowing any two qualified operators to perform the procedure. Our program has enough surgeons specializing in both TAVR and surgery to dedicate specific days to TAVR. Smaller programs may have only one or two surgeons whose surgical responsibilities make scheduling difficult. Allowing an interventionalist to perform TAVR without a surgeon as the second operator frees the surgeon for surgery, and the reverse frees the interventionalist for other cases. The intent is to let programs choose the approach that best meets their patients’ needs.
1. Centers for Medicare & Medicaid Services. National Coverage Analysis (NCA): Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R2)—Decision Memo. Published September 10, 2026. Accessed October 1, 2026. https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?NCAId=321
2. Généreux P, Schwartz A, Oldemeyer JB, et al; EARLY TAVR Trial investigators. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N Engl J Med. 2025;392:217-227. doi: 10.1056/NEJMoa2405880
Disclosures
Dr. Szerlip: Unavailable at the time of publication.
Advertisement
Advertisement
Latest Digital Exclusives